Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Upadacitinib effectively treated alopecia areata when other treatments failed.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

CTP-543 is generally safe for treating alopecia areata.

Upadacitinib effectively treated alopecia areata when other treatments failed.

Erlotinib may cause scarring hair loss.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Certain cancer drugs can cause skin issues like rashes and itching.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Blocking mTORC1 reduces skin tumor growth in mice.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.